Last reviewed · How we verify
Licensed COVID-19 Vaccine
The vaccine uses mRNA to instruct cells to produce a harmless piece of the spike protein, triggering an immune response.
At a glance
| Generic name | Licensed COVID-19 Vaccine |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Biologic |
| Phase | Phase 1 |
Mechanism of action
This mRNA vaccine delivers genetic instructions to your cells, which then produce a piece of the SARS-CoV-2 spike protein. The immune system recognizes this protein as foreign and mounts a defense, preparing to fight off future infections.
Approved indications
Common side effects
- Headache
- Injection site pain
- Fatigue
- Myalgia
- Chills
- Pyrexia
- Fatigue (FATIGUE)
- Injection site pain (PAIN)
- Headache (HEADACHE)
- Chills (CHILLS)
- Myalgia (MUSCLE PAIN)
- Injection site pain (PAIN AT THE INJECTION SITE) left deltoid
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)
- Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age (PHASE3)
- Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults (PHASE1)
- A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed COVID-19 Vaccine CI brief — competitive landscape report
- Licensed COVID-19 Vaccine updates RSS · CI watch RSS
- BioNTech SE portfolio CI